Experimental HCV Drugs
Experimental HCV Drugs
EASL 2014: Idenix Hepatitis C Drugs Look Promising in Early Studies
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 06 May 2014 00:00
- Written by HIVandHepatitis.com
Idenix Pharmaceuticals' hepatitis C virus NS5A inhibitor samatasvir (formerly IDX179) plus Janssen's HCV protease inhibitor simeprevir (Olysio) and ribavirin produced early sustained virological response rates of about 80% in a small study presented at the 49th EASL International Liver Congress last month in London. Another study showed that the company's HCV polymerase inhibitor candidate IDX21437 looks good in preclinical studies and is a potential once-daily partner for samatasvir in interferon-free regimens.
Achillion Announces Start of Studies of ACH-3422 and ACH-3102 for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 02 May 2014 00:00
- Written by Achillion
Achillion Pharmaceuticalsannounced this week that the first participants have started receiving treatment in a Phase 1 clinical trial testing the investigational nucleotide hepatitis C virus (HCV) polymerase inhibitor ACH-3422. In addition, a recently initiated Phase 2 study is evaluating the company's next-generation NS5A inhibitor ACH-3012 in combination with Gilead Sciences' sofosbuvir (Sovaldi) for as little as 8 or even 6 weeks.
AbbVie Requests FDA Approval of Interferon-free "3D" Combo for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 25 April 2014 00:00
- Written by AbbVie
AbbVie announced this week that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval of its "3D" regimen of direct-acting antivirals -- ABT-450/ritonavir, ombitasvir (ABT-267), and dasabuvir (ABT-333), to be used with or without ribavirin. 3D has been designated as an FDA "breakthrough therapy" and an approval decision is expected by the end of the year.
EASL 2014: Sofosbuvir + Ribavirin for 24 Weeks Is Highly Effective Against HCV Genotype 4
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 29 April 2014 00:00
- Written by Liz Highleyman
A 24-week regimen of sofosbuvir (Sovaldi) plus ribavirin cured 93% of people with hard-to-treat hepatitis C virus (HCV) genotype 4, though treatment for only 12 weeks was not as effective, according to a poster presentation at the EASL International Liver Congress this month in London.
EASL 2014: Sofosbuvir Works Well Despite Multiple Negative Predictive Factors
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 22 April 2014 00:00
- Written by Liz Highleyman
Hepatitis C treatment using sofosbuvir (Sovaldi) is highly effective even for people with multiple factors traditionally associated with poor response. Having 4 or more negative predictive factors, however, raises the risk of post-treatment relapse, according to a report at the 49th EASL International Liver Congress held recently in London.
More Articles...
- AbbVie Combination Safe and Highly Effective in Patients with Post-Transplant HCV Recurrence
- EASL 2014: Sofosbuvir + GS-5816 NS5A Inhibitor Is Effective Against HCV Genotypes 1-6
- EASL 2014: MK-5172 + MK-8742 Demonstrate Good Early Post-Treatment Response Rates
- EASL 2014: AbbVie 2-Drug Combo + Ribavirin Cures 100% of Previously Untreated HCV Genotype 4
Web Design and Development by